Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation fo… Read more
Evelo Biosciences Inc (EVLO) - Total Liabilities
Latest total liabilities as of September 2023: $47.33 Million USD
Based on the latest financial reports, Evelo Biosciences Inc (EVLO) has total liabilities worth $47.33 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evelo Biosciences Inc - Total Liabilities Trend (2016–2022)
This chart illustrates how Evelo Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Evelo Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Evelo Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CVK Maden Isletmeleri Sanayi ve Ticaret A.S.
IS:CVKMD
|
Turkey | TL12.72 Billion |
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
Vietnam | ₫13.52 Billion |
|
SEABIRD EXP
MU:E36
|
Germany | €22.17 Million |
|
CHINA UNICOM (HK) - Dusseldorf Stock Exchang
DU:XCI
|
Germany | €307.15 Billion |
|
Intek Group SpA
STU:MTJ3
|
Germany | €1.49 Billion |
|
Iscom Online International Information Inc.
TWO:6868
|
Taiwan | NT$526.43 Million |
Liability Composition Analysis (2016–2022)
This chart breaks down Evelo Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evelo Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evelo Biosciences Inc (2016–2022)
The table below shows the annual total liabilities of Evelo Biosciences Inc from 2016 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $69.43 Million | -12.34% |
| 2021-12-31 | $79.20 Million | +31.67% |
| 2020-12-31 | $60.15 Million | +95.79% |
| 2019-12-31 | $30.72 Million | +34.06% |
| 2018-12-31 | $22.92 Million | +59.32% |
| 2017-12-31 | $14.38 Million | +10.28% |
| 2016-12-31 | $13.04 Million | -- |